OLOL Inpatient Automatic Dose Rounding Protocol

Revised: 11/01/2022

Purpose: To maintain a protocol of rounding weight-based medication dosages to fit with available product sizes, which is consistent with safe administration and minimal risk, while maintaining optimal therapeutic response. Actual body weight or Total Body Weight (TBW) will be used, unless stated otherwise.

Weight (kg)
▪ Actual Body Weight or Total Body Weight (TBW): current weight
▪ Ideal Body Weight (IBW): ○ IBW_{male}: 50 kg + (2.3 x height in inches > 60 inches) ○ IBW_{female}: 45 kg + (2.3 x height in inches > 60 inches)
▪ Dosing Weight (DW) or "Adjusted Weight": TBW ≥120% of IBW ○ IBW + 0.4 (TBW - IBW)

Weight Classification

Normal weight: TBW > IBW, TBW/IBW <120%

Obese: TBW/IBW ≥120%

Underweight: TBW < IBW

Documentation:

- Place a comment in the administration instructions field of medication order "automatic dose rounding per P&T approved protocol"
- Open an I-Vent for **Dose Change** and document rounding
- In addition to documentation, the following medications must be rejected and reordered for provider co-signature: Aldesleukin, bevacizumab, denileukin, IVIG, rituximab, trastuzumab

Medications (click)	
Acyclovir	Ganciclovir
Aldesleukin	Gentamicin
Amikacin	Immune Globulin (IVIG)
Amphotericin, liposomal	Infliximab (Inflectra) vs (Remicade)*
Bevacizumab	Rituximab
Daptomycin	Sulfamethoxazole/trimethoprim IV
Denileukin	Tobramycin
Enoxaparin	Tocilizumab*
Eravacycline	Trastuzumab
Factor products	Vancomycin
Flucytosine	Voriconazole
Filgrastim (tbo-filgrastim)	

Acyclovir Underweight: TBW Normal weight: IBW Obese: DW	
Doses ending in	**Round by 50mg**
1-49mg	Up to even 50mg
51-99mg	Up to even 100mg

Aldesleukin
Round down to the nearest vial size within 10%; if unable, round to the nearest 1million units.

Amikacin Underweight: TBW Normal weight: IBW Obese: DW	
Doses ending in	**Round by 50mg**
1-49mg	Up to even 50mg
51-99mg	Up to even 100mg

Amphotericin, liposomal Underweight: TBW Normal weight: TBW Obese: DW	
Doses ending in	**Round by 50mg**
1-49mg	Up to even 50mg
51-99mg	Up to even 100mg

Bevacizumab
Round down to the nearest 100mg as long as the rounded dose is within 10% of the original dose; if >10%, round to the nearest 10mg.

Daptomycin Underweight: TBW Normal weight: TBW Obese: DW	
Doses ending in	**Round by 50mg**
1-49mg	Up to even 50mg
51-99mg	Up to even 100mg

Denileukin
Round down to the nearest vial size within 10%; if unable, round to the nearest 10mcg.

Enoxaparin		
Wt range (kg)	Dose	Syringe size to dispense
40-45	40mg	40mg
46-55	50mg	60mg
56-65	60mg	60mg
66-75	70mg	80mg
76-85	80mg	80mg
86-95	90mg	100mg
96-105	100mg	100mg
106-115	110mg	120mg
116-125	120mg	120mg
126-135	130mg	150mg
136-145	140mg	150mg
146-155	150mg	150mg
>155kg Insufficient data in Acute Coronary Syndrome (ACS) and Deep Vein Thrombosis (DVT) treatment. Physician will be contacted.		

Eravacycline Underweight: TBW Normal weight: TBW Obese: TBW	
Doses ending in	**Round by 10mg**
1-4mg	Down to even 10mg
5-9mg	Up to even 10mg

Factor products
Intermittent - round to the nearest vial size within 10% of the original dose. Continuous infusions - no rounding will be done for continuous infusions of factor products.

Filgrastim (tbo-filgrastim) 5mcg/kg	
Weight	**Dose**
<60 kg	300mcg
≥ 60kg	480mcg

Flucytosine Underweight: TBW Normal weight: TBW Obese: IBW
Round up to the nearest 500mg capsule.

Ganciclovir Underweight: TBW Normal weight: TBW Obese: TBW	
Doses ending in	**Round by 50mg**
1-49mg	Up to even 50mg
51-99mg	Up to even 100mg

Gentamicin Underweight: TBW Normal weight: IBW Obese: DW	
Doses ending in	**Round by 10mg**
1-4mg	Down to even 10mg
5-9mg	Up to even 10mg

Immune Globulin (IVIG) [IBW] [DW] if TBW/IBW ≥120%
Round down to the nearest vial size within 10%.

Infliximab (Inflectra) vs (Remicade)*
Round down to the nearest 100mg as long as the rounded dose is within 10% of the original dose; if >10%, round to the nearest 10mg. Interchange Remicade for Inflectra. **Remicade is restricted to the Outpatient setting except for Inpatient use by gastroenterologists in patients with Crohn's disease or ulcerative colitis who are nearing obstruction.*

Rituximab
Round down to the nearest 100mg as long as the rounded dose is within 10% of the original dose; if >10%, round to the nearest 10mg.

Sulfamethoxazole/trimethoprim IV Based on trimethoprim component Underweight: TBW Normal weight: TBW Obese: DW	
Doses ending in	**Round by 40mg**
1-40mg	Up to even 40mg
41-80mg	Up to even 80mg
81-99mg	Down to even 80mg

Tobramycin Underweight: TBW Normal weight IBW Obese: DW	
Doses ending in	**Round by 10mg**
1-4mg	Down to even 10mg
5-9mg	Up to even 10mg

Tocilizumab*
Round down to the nearest vial size as long as the rounded dose is within 10% of the original dose; if >10%, round to the nearest 10mg. *Tocilizumab (Actemra) is temporarily approved for use in cytokine storm related to COVID-19. Please reach out to Pharmacy Leadership for acquisition.

Trastuzumab
Round down to the nearest vial size as long as the rounded dose is within 10% of the original dose; if >10%, round to the nearest 10mg.

Vancomycin Underweight: TBW Normal weight: TBW Obese: TBW	
Doses	**Round**
Doses ≥375 mg to ≤624 mg	Round dose to 500mg
Doses ≥625 mg to ≤874 mg	Round dose to 750mg
Doses ≥875 mg to ≤1124 mg	Round dose to 1000mg
Doses ≥1125 mg to ≤1374 mg	Round dose to 1250mg
Doses ≥1375 mg to ≤1624 mg	Round dose to 1500mg
Doses ≥1625 mg to ≤1874 mg	Round dose to 1750mg
Doses ≥1875 mg to any dose higher than 2000 mg	Round dose to 2000mg

Voriconazole Underweight: TBW Normal weight: TBW Obese: DW	
Doses ending in	**Round by 50mg**
1-49mg	Up to even 50mg
51-99mg	Up to even 100mg

References:

1. Polso AK, Lassiter JL, Gagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther. 2014 Dec;39(6):584-608.

Acyclovir

1. Turner RB, Cumpston A, Sweet M, et al. Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. Antimicrob Agents Chemother. 2016 Mar; 60(3): 1830–1833.
2. Mulvey N, Jain S, Falsetta K, et al. Assessing the Clinical Impact of Intravenous Acyclovir Dosing in Obese Patients: Should We Be Using Ideal, Adjusted, or Total Body Weight? Open Forum Infect Dis. 2020 Oct; 7(Supplemental):S102-103.

Aminoglycosides

1. Schwartz SN, Pazin GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis, 1978;138:499–505.
2. Blouin RA, Mann HJ, Griffen WO Jr, et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther, 1979;26:508–512.
3. Korsager S. Administration o gentamicin to obese patients. Int J Clin Pharmacol Ther Toxicol, 1980;18:549–553.
4. Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24:643–647.
5. Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet, 2004;43:1167–1178.
6. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011;55:4006–4011.

Amphotericin, Liposomal

1. Groll AH, Mickiene D, Piscitelli SC, Walsh TJ. Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother. 2000;44:408–410.
2. Ting M, Spec A, Micek S, et al. Evaluation of Total Body Weight versus Adjusted Body Weight Liposomal Amphotericin B Dosing in Obese Patients. Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0236620.
3. Wasmann R, Smit C, van Dongen E, et al. Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. Clin Infect Dis. 2020 May 6;70(10):2213-2215.

Daptomycin

1. Pai MP, Norenberg JP, Anderson T et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007;51:2741–2747.
2. Farkas, A. 1634. Dosing of Daptomycin in the Morbidly Obese: Which Body Weight is it?. ID Week 2012. [abstract]
3. Ng, J, Schulz L, Rose W, et al. Daptomycin Dosing Based on Ideal Body Weight versus Actual Body Weight: Comparison of Clinical Outcomes. Antimicrob Agents Chemother. 2014 Jan; 58(1): 88–93.
4. Fox A, Smith W, Kupiec, et al. Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight Ther Adv Infect Dis. 2019 Jan-Dec; 6: 2049936118820230.

Flucytosine

1. Gillum JG, Johnson M, Lavoie S, et al. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy. 1995;15(2):251-3.
2. Miller MM, Kreikemeier E, Stohs EJ, Van Schooneveld TC, Alexander B, Bergman SJ. 161. Flucytosine Utilization and Dosing Practices at an Academic Medical Center. Open Forum Infect Dis 2021; 8(Suppl_1):S191.

Ganciclovir

1. See Lexi-Comp entry for systemic Ganciclovir.

Voriconazole

1. Khalid Eljaaly, David E. Nix, Voriconazole Dosing in Obese Patients, Clinical Infectious Diseases, Volume 63, Issue 2, 15 July 2016, Pages 286–287, https://doi.org/10.1093/cid/ciw252
2. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother. 2011 Jun;55(6):2601-5.
3. Mourad A, Johnson M, Perfect J. Dosing voriconazole in obese patients. Op For Infect Dis. 2017;4(suppl_1):S292-S293.
4. Koselke E, Kraft S, Smith J, Nagel J. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother 2012; 67(12):2957-62.
5. 5. Diller E, Krekel T, Spec A, Klaus J. Evaluation of Total Body Weight versus Adjusted Body Weight Voriconazole Dosing in Obese Patients. Antimicrob Agents Chemother 2021; 65(7): e0246020.